{"pmid":32426209,"pmcid":"PMC7228888","title":"Are Type 1 Interferons treatment in Multiple Sclerosis as a potential therapy against COVID-19?","text":["Are Type 1 Interferons treatment in Multiple Sclerosis as a potential therapy against COVID-19?","Background: : The Coronavirus (COVID-19), (Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)) has been spreading worldwide since its first identification in China. It has been speculated that patients with comorbidities and elderly patients could be at high risk for the pandemic reasoned respiratory insufficiency and death. At first, it was thought that the patients who use immunmodulator therapy could be even at higher risks of disease complications. However, it has been also speculated about that using immunmodulators could be an advantage for the clinical prognosis. Therefore, several immunmodulators are currently being tested as potential treatment for COVID-19. Methods: : In this paper we report on a patient that has been treated with type 1 interferon for multiple sclerosis who developed COVID-19. Results: : Despite using immunmodulator, the symptoms of the patient at hospitalization were mild and he did not show elevated D-dimer, and there was no lymphopenia. He was discharged to home-quarantine with no symptoms. Discussion: : This report supports the idea of using type 1 interferon in the treatment could be effective in COVID-19 affected patients.","Mult Scler Relat Disord","Gemcioglu, Emin","Davutoglu, Mehmet","Ozdemir, Ese Ece","Erden, Abdulsamet","32426209"],"abstract":["Background: : The Coronavirus (COVID-19), (Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)) has been spreading worldwide since its first identification in China. It has been speculated that patients with comorbidities and elderly patients could be at high risk for the pandemic reasoned respiratory insufficiency and death. At first, it was thought that the patients who use immunmodulator therapy could be even at higher risks of disease complications. However, it has been also speculated about that using immunmodulators could be an advantage for the clinical prognosis. Therefore, several immunmodulators are currently being tested as potential treatment for COVID-19. Methods: : In this paper we report on a patient that has been treated with type 1 interferon for multiple sclerosis who developed COVID-19. Results: : Despite using immunmodulator, the symptoms of the patient at hospitalization were mild and he did not show elevated D-dimer, and there was no lymphopenia. He was discharged to home-quarantine with no symptoms. Discussion: : This report supports the idea of using type 1 interferon in the treatment could be effective in COVID-19 affected patients."],"journal":"Mult Scler Relat Disord","authors":["Gemcioglu, Emin","Davutoglu, Mehmet","Ozdemir, Ese Ece","Erden, Abdulsamet"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32426209","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.msard.2020.102196","locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Case Report"],"weight":1,"_version_":1667252837684346880,"score":9.490897,"similar":[{"pmid":32480326,"title":"Are type 1 interferons treatment in Multiple Sclerosis as a potential therapy against COVID-19?","text":["Are type 1 interferons treatment in Multiple Sclerosis as a potential therapy against COVID-19?","BACKGROUND: The Coronavirus (COVID-19), (Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)) has been spreading worldwide since its first identification in China. It has been speculated that patients with comorbidities and elderly patients could be at high risk for the pandemic reasoned respiratory insufficiency and death. At first, it was thought that the patients who use immunmodulator therapy could be even at higher risks of disease complications. However, it has been also speculated about that using immunmodulators could be an advantage for the clinical prognosis. Therefore, several immunmodulators are currently being tested as potential treatment for COVID-19. METHODS: In this paper we report on a patient that has been treated with type 1 interferon for multiple sclerosis who developed COVID-19. RESULTS: Despite using immunmodulator, the symptoms of the patient at hospitalization were mild and he did not show elevated D-dimer, and there was no lymphopenia. He was discharged to home-quarantine with no symptoms. DISCUSSION: This report supports the idea of using type 1 interferon in the treatment could be effective in COVID-19 affected patients.","Mult Scler Relat Disord","Gemcioglu, Emin","Davutoglu, Mehmet","Ozdemir, Ese Ece","Erden, Abdulsamet","32480326"],"abstract":["BACKGROUND: The Coronavirus (COVID-19), (Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)) has been spreading worldwide since its first identification in China. It has been speculated that patients with comorbidities and elderly patients could be at high risk for the pandemic reasoned respiratory insufficiency and death. At first, it was thought that the patients who use immunmodulator therapy could be even at higher risks of disease complications. However, it has been also speculated about that using immunmodulators could be an advantage for the clinical prognosis. Therefore, several immunmodulators are currently being tested as potential treatment for COVID-19. METHODS: In this paper we report on a patient that has been treated with type 1 interferon for multiple sclerosis who developed COVID-19. RESULTS: Despite using immunmodulator, the symptoms of the patient at hospitalization were mild and he did not show elevated D-dimer, and there was no lymphopenia. He was discharged to home-quarantine with no symptoms. DISCUSSION: This report supports the idea of using type 1 interferon in the treatment could be effective in COVID-19 affected patients."],"journal":"Mult Scler Relat Disord","authors":["Gemcioglu, Emin","Davutoglu, Mehmet","Ozdemir, Ese Ece","Erden, Abdulsamet"],"date":"2020-06-02T11:00:00Z","year":2020,"_id":"32480326","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1016/j.msard.2020.102196","locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Case Report"],"weight":1,"_version_":1668437834978033664,"score":761.9808},{"pmid":32315980,"pmcid":"PMC7156942","title":"COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role?","text":["COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role?","BACKGROUND: Coronavirus disease 19 (COVID-19) is a novel disease entity that is spreading throughout the world. It has been speculated that patients with comorbidities and elderly patients could be at high risk for respiratory insufficiency and death. Immunosuppression could expose infected patients to even higher risks of disease complications due to dampened immune response. However, it has been speculated that overactive immune response could drive clinical deterioration and, based on this hypothesis, several immunosuppressants are currently being tested as potential treatment for COVID-19. METHODS: In this paper we report on a patient that has been treated with ocrelizumab (a B-cell depleting monoclonal antibody) for primary progressive multiple sclerosis who developed COVID-19. RESULTS: Despite complete B cell depletion, patient symptoms abated few days after hospitalization, and he was discharged to home-quarantine. Phone interview follow-up confirmed that, after 14 days, no new symptoms occurred. DISCUSSION: This report supports the putative role of immunosuppressive therapy in COVID-19 affected patients.","Mult Scler Relat Disord","Novi, Giovanni","Mikulska, Malgorzata","Briano, Federica","Toscanini, Federica","Tazza, Francesco","Uccelli, Antonio","Inglese, Matilde","32315980"],"abstract":["BACKGROUND: Coronavirus disease 19 (COVID-19) is a novel disease entity that is spreading throughout the world. It has been speculated that patients with comorbidities and elderly patients could be at high risk for respiratory insufficiency and death. Immunosuppression could expose infected patients to even higher risks of disease complications due to dampened immune response. However, it has been speculated that overactive immune response could drive clinical deterioration and, based on this hypothesis, several immunosuppressants are currently being tested as potential treatment for COVID-19. METHODS: In this paper we report on a patient that has been treated with ocrelizumab (a B-cell depleting monoclonal antibody) for primary progressive multiple sclerosis who developed COVID-19. RESULTS: Despite complete B cell depletion, patient symptoms abated few days after hospitalization, and he was discharged to home-quarantine. Phone interview follow-up confirmed that, after 14 days, no new symptoms occurred. DISCUSSION: This report supports the putative role of immunosuppressive therapy in COVID-19 affected patients."],"journal":"Mult Scler Relat Disord","authors":["Novi, Giovanni","Mikulska, Malgorzata","Briano, Federica","Toscanini, Federica","Tazza, Francesco","Uccelli, Antonio","Inglese, Matilde"],"date":"2020-04-22T11:00:00Z","year":2020,"_id":"32315980","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.msard.2020.102120","e_drugs":["ocrelizumab"],"topics":["Case Report"],"weight":1,"_version_":1666138493504454656,"score":239.94368},{"pmid":32443163,"title":"Interferons in the Therapy of Severe Coronavirus Infections: A Critical Analysis and Recollection of a Forgotten Therapeutic Regimen with Interferon Beta.","text":["Interferons in the Therapy of Severe Coronavirus Infections: A Critical Analysis and Recollection of a Forgotten Therapeutic Regimen with Interferon Beta.","The pharmacological and immunological properties of interferons, especially those of interferon beta, and the corresponding treatment strategies are described, and the results of studies with different interferons in coronavirus infections are analysed. Furthermore, the data obtained with high-dosed native interferon beta in life-threatening acute viral diseases as well as the results of clinical pilot studies with high-dosed recombinant interferon beta-1a are provided because they serve as the rationale for the proposed therapeutic regimen to be applied in acute viral infections. This regimen differs from those approved for treatment of multiple sclerosis and consists of interferon beta-1a administered as a 24 hour intravenous infusion at a daily dose of up to 90 microg for 3-5 consecutive days. Since under this regimen transient severe side effects can occur, it is analysed which patients are suitable for this kind of treatment in general and if patients with severe coronavirus infections could also be treated accordingly.","Drug Res (Stuttg)","Brzoska, Josef","von Eick, Harald","Hundgen, Manfred","32443163"],"abstract":["The pharmacological and immunological properties of interferons, especially those of interferon beta, and the corresponding treatment strategies are described, and the results of studies with different interferons in coronavirus infections are analysed. Furthermore, the data obtained with high-dosed native interferon beta in life-threatening acute viral diseases as well as the results of clinical pilot studies with high-dosed recombinant interferon beta-1a are provided because they serve as the rationale for the proposed therapeutic regimen to be applied in acute viral infections. This regimen differs from those approved for treatment of multiple sclerosis and consists of interferon beta-1a administered as a 24 hour intravenous infusion at a daily dose of up to 90 microg for 3-5 consecutive days. Since under this regimen transient severe side effects can occur, it is analysed which patients are suitable for this kind of treatment in general and if patients with severe coronavirus infections could also be treated accordingly."],"journal":"Drug Res (Stuttg)","authors":["Brzoska, Josef","von Eick, Harald","Hundgen, Manfred"],"date":"2020-05-23T11:00:00Z","year":2020,"_id":"32443163","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1055/a-1170-4395","topics":["Treatment"],"weight":1,"_version_":1667523504887562240,"score":145.82703},{"pmid":32477373,"pmcid":"PMC7235419","title":"Implications of COVID-19 Outbreak on Immune Therapies in Multiple Sclerosis Patients-Lessons Learned From SARS and MERS.","text":["Implications of COVID-19 Outbreak on Immune Therapies in Multiple Sclerosis Patients-Lessons Learned From SARS and MERS.","Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic keeps the world in suspense. In addition to the fundamental challenges for the health care system, the individual departments must decide how to deal with patients at risk. Neurologists are confronted with the question, how they should advise their patients regarding immunosuppressive treatment. In particular, the large number of different disease-modifying therapies (DMTs) in the treatment of neuroimmunological diseases such as multiple sclerosis poses a challenge. To a limited extent, it might be useful to transfer knowledge from previous SARS- and Middle East respiratory syndrome (MERS) coronavirus outbreaks in 2002/2003 and 2012 to the current situation. Overall, immunosuppressive therapy does neither seem to have a major impact on infection with SARS- and MERS-CoV nor does it seem to lead to a severe disease course in many cases. Considering the immunological responses against infections with novel coronaviruses in humans, interferons, glatiramer acetate, and teriflunomide appear to be safe. As lymphopenia seems to be associated with a more severe disease course, all DMTs causing lymphopenia, such as cladribine, alemtuzumab, and dimethyl fumarate, need to be reviewed more thoroughly. As they are, in general, associated with a higher risk of infection, depleting anti-CD20 antibodies may be problematic drugs. However, it has to be differentiated between the depletion phase and the phase of immune reconstitution. In summary, previous coronavirus outbreaks have not shown an increased risk for immunocompromised patients. Patients with severe neuroimmunological diseases should be kept from hasty discontinuation of immunotherapy.","Front Immunol","Mohn, Nora","Pul, Refik","Kleinschnitz, Christoph","Pruss, Harald","Witte, Torsten","Stangel, Martin","Skripuletz, Thomas","32477373"],"abstract":["Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic keeps the world in suspense. In addition to the fundamental challenges for the health care system, the individual departments must decide how to deal with patients at risk. Neurologists are confronted with the question, how they should advise their patients regarding immunosuppressive treatment. In particular, the large number of different disease-modifying therapies (DMTs) in the treatment of neuroimmunological diseases such as multiple sclerosis poses a challenge. To a limited extent, it might be useful to transfer knowledge from previous SARS- and Middle East respiratory syndrome (MERS) coronavirus outbreaks in 2002/2003 and 2012 to the current situation. Overall, immunosuppressive therapy does neither seem to have a major impact on infection with SARS- and MERS-CoV nor does it seem to lead to a severe disease course in many cases. Considering the immunological responses against infections with novel coronaviruses in humans, interferons, glatiramer acetate, and teriflunomide appear to be safe. As lymphopenia seems to be associated with a more severe disease course, all DMTs causing lymphopenia, such as cladribine, alemtuzumab, and dimethyl fumarate, need to be reviewed more thoroughly. As they are, in general, associated with a higher risk of infection, depleting anti-CD20 antibodies may be problematic drugs. However, it has to be differentiated between the depletion phase and the phase of immune reconstitution. In summary, previous coronavirus outbreaks have not shown an increased risk for immunocompromised patients. Patients with severe neuroimmunological diseases should be kept from hasty discontinuation of immunotherapy."],"journal":"Front Immunol","authors":["Mohn, Nora","Pul, Refik","Kleinschnitz, Christoph","Pruss, Harald","Witte, Torsten","Stangel, Martin","Skripuletz, Thomas"],"date":"2020-06-02T11:00:00Z","year":2020,"_id":"32477373","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.3389/fimmu.2020.01059","keywords":["covid-19","dmts","mers","sars","immunosuppressive therapy","multiple sclerosis"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1668437835081842688,"score":139.37935},{"pmid":32408155,"pmcid":"PMC7202802","title":"Severe COVID-19 infection in a patient with multiple sclerosis treated with fingolimod.","text":["Severe COVID-19 infection in a patient with multiple sclerosis treated with fingolimod.","BACKGROUND: Fingolimod is used for immune therapy in patients with multiple sclerosis. Long-term treatment is associated with a small increase in the risk of herpes virus reactivation and respiratory tract infections. Patients with coronavirus disease 2019 (COVID-19) under Fingolimod treatment have not been described. METHODS AND RESULTS: We report a 57-year old female patient with a relapsing remitting multiple sclerosis under fingolimod treatment who experienced a severe COVID-19 infection in March 2020 (Extended Disability Status Scale: 2.0). Having peripheral lymphopenia typical for fingolimod treatment (total lymphocytes 0.39/nL [reference range 1.22-3.56]), the patient developed bilateral interstitial pneumonia with multiple ground-glass opacities on chest CT. Fingolimod medication was stopped. On the intensive care unit, non-invasive ventilation was used to provide oxygen and ventilation support regularly. Over the following two days, oxygenation improved, and the patient was transferred to a normal ward five days after admission. CONCLUSION: The implications fingolimod has on COVID-19 are complex. As an S1P analogue, fingolimod might enhance lung endothelial cell integrity. In addition, in case of a so-called cytokine storm, immunomodulation might be beneficial to reduce mortality. Future studies are needed to explore the risks and therapeutic effects of fingolimod in COVID-19 patients.","Mult Scler Relat Disord","Foerch, Christian","Friedauer, Lucie","Bauer, Boris","Wolf, Timo","Adam, Elisabeth H","32408155"],"abstract":["BACKGROUND: Fingolimod is used for immune therapy in patients with multiple sclerosis. Long-term treatment is associated with a small increase in the risk of herpes virus reactivation and respiratory tract infections. Patients with coronavirus disease 2019 (COVID-19) under Fingolimod treatment have not been described. METHODS AND RESULTS: We report a 57-year old female patient with a relapsing remitting multiple sclerosis under fingolimod treatment who experienced a severe COVID-19 infection in March 2020 (Extended Disability Status Scale: 2.0). Having peripheral lymphopenia typical for fingolimod treatment (total lymphocytes 0.39/nL [reference range 1.22-3.56]), the patient developed bilateral interstitial pneumonia with multiple ground-glass opacities on chest CT. Fingolimod medication was stopped. On the intensive care unit, non-invasive ventilation was used to provide oxygen and ventilation support regularly. Over the following two days, oxygenation improved, and the patient was transferred to a normal ward five days after admission. CONCLUSION: The implications fingolimod has on COVID-19 are complex. As an S1P analogue, fingolimod might enhance lung endothelial cell integrity. In addition, in case of a so-called cytokine storm, immunomodulation might be beneficial to reduce mortality. Future studies are needed to explore the risks and therapeutic effects of fingolimod in COVID-19 patients."],"journal":"Mult Scler Relat Disord","authors":["Foerch, Christian","Friedauer, Lucie","Bauer, Boris","Wolf, Timo","Adam, Elisabeth H"],"date":"2020-05-15T11:00:00Z","year":2020,"_id":"32408155","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.msard.2020.102180","keywords":["covid-19","critical care","fingolimod","multiple sclerosis","viral infection"],"e_drugs":["Fingolimod Hydrochloride"],"topics":["Case Report"],"weight":1,"_version_":1666950579862110208,"score":137.39769}]}